Massachusetts Governor Deval Patrick to address BioPharm America™ 2011

September 6, 2011
EBD Group and MassBio today announced that Massachusetts Governor Deval Patrick will make a special visit to BioPharm America 2011. Governor Patrick will address leaders in the global life science industry during an event at The State Room at 60 State Street in Boston on Wednesday, September 7 at 7:00 pm.

“We are honored to have Governor Deval Patrick address the BioPharm America delegation,” said Bob Coughlin, President and CEO of MassBio. “The life science industry is vital part of Massachusetts’ economic fabric. This event is a unique opportunity to highlight how our companies continue to be the most innovative in the industry.”

Carola Schropp, President of EBD Group, the leading partnering firm in the life science industry added, “The BioPharm America conference is one of the largest business exchanges in the world. It is where the leading dealmakers come to strike the deals and collaborations resulting in tomorrow’s novel medicines. Governor Patrick is one of the most important advocates for our industry and we are excited to have him speak at our event.”

On June 16, 2008, Governor Patrick signed into law his groundbreaking 10-year, USD 1 billion Life Sciences Initiative, positioning Massachusetts as a global leader in life sciences and bringing together research hospitals, businesses, and universities to enhance the state's nationally-recognized strengths in medicine and science. 

“We want Massachusetts to provide the global platform for bringing innovations from the drawing board to the market, from inspiration to commercialization, and from ideas to cures,” said Patrick in 2007, when introducing his bill.

With more than 1,000 dealmakers expected, BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe® and BIO-Europe Spring®, and was specifically designed to help companies form in- or out-licensing agreements and co-development deals, and raise capital.

MassBio estimates that 1,273 biotechnology drugs were being developed in Massachusetts in 2010, representing almost eight percent of the global drug pipeline. In 2010, Massachusetts companies garnered more than 23 percent of all of the biotechnology venture capital funding in the US, an all-time high.

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Upcoming Events email!
For Email Marketing you can trust

MassBio